Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Positive HBsAg \>= 6 months prior to randomization and positive HBeAg at screening.~* Serum HBV DNA greater than or equal to 1 x 100,000 copies/mL (PCR assay) at initial or confirmatory screening visit.~* Serum ALT levels greater than or equal to 1.5 x ULN at both initial and confirmatory screening visits.~* Compensated liver disease with anticipated survival greater than 12 months and with the following laboratory and clinical parameters within 4 weeks of baseline: \*Prothrombin time less than or equal to 1 second above normal range. \*Total bilirubin less than 1.3 mg/dL or normal direct bilirubin. \*Serum albumin greater than 3 g/dL (greater than 30 g/L). \*No clinical history of ascites, variceal bleeding, encephalopathy or splenomegaly. \*Adequate renal function defined as creatinine clearance greater than or equal to 80 mL/min (calculated using Schwartz Formula).~Key Exclusion Criteria:~* Received immunoglobulin, interferon or lamivudine therapy within 6 months prior to initial screening visit.~* Participated in any investigational trial with any investigational compound within 2 months prior to initial screening.~* Organ or bone marrow transplant recipients.~* Clinical evidence of decompensated liver disease.~* A Child-Pugh-Turcotte score greater than 6.~* Inability to comply with study requirements.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (PLB) (Type: PLACEBO_COMPARATOR): Participants randomized to receive placebo received placebo during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
- Adefovir Dipivoxil (ADV) (Type: EXPERIMENTAL): Participants randomized to receive ADV received ADV during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).